A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab, pomalidomide, and dexamethasone], PVd [pomalidomide, bortezomib and dexamethasone], or Kd [carfilzomib and dexamethasone]) in participants with RRMM.

Start Date23 Feb 2026

Sponsor / Collaborator

AstraZeneca PLC

NCT07364487

/ WithdrawnEarly Phase 1IIT

An Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

This is an open-label,early-stage exploratory clinical study to evaluate the safety and preliminary efficacy of GC012F CAR T cell injection in Multiple Sclerosis subjects.

Start Date26 Jan 2026

Sponsor / Collaborator

Shanghai Huashan Hospital

NCT07303790

/ RecruitingEarly Phase 1IIT

An Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

This is an early exploratory study to assess the tolerability and safety of GC012F CAR T cell injection in Multiple Sclerosis patients.

Start Date16 Jan 2026

Sponsor / Collaborator

Huazhong University of Science Tongji Hospital, Tongji Medical College

100 Clinical Results associated with GC-012F

100 Translational Medicine associated with GC-012F

100 Patents (Medical) associated with GC-012F

Literatures (Medical) associated with GC-012F

01 Nov 2025·Transplantation and Cellular Therapy

Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies

Review

Author: Maloney, David G ; Locke, Frederick L ; Shah, Nirav N ; Neelapu, Sattva S ; Ng, Eric ; Davila, Marco ; Vong, Judy ; Jacobson, Caron ; Miklos, David B ; Nikiforow, Sarah ; Welch, John ; Lin, Yi ; Maus, Marcela V ; Frigault, Matthew J

Chimeric antigen receptor T-cell (CAR T) therapies have demonstrated potential to provide long-term remission in incurable hematologic malignancies, and novel approaches for CAR T therapy continue to be developed for treating cancer and other indications. Acute class-effect toxicities, such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, remain significant concerns despite their potential reversibility. Given the complexities of balancing safety and efficacy of CAR T therapies, the US Food and Drug Administration (FDA) recently published Guidance for Industry, which included suggested definitions for dose-limiting toxicities (DLTs) for clinical trials of emerging CAR T therapies. However, the DLT definitions in the guidance do not reflect what was used in the phase 1 and/or registrational studies for the approved CAR Ts; for example, these studies defined DLTs as treatment-related, included exceptions, and/or allowed for time to resolve the adverse event. Using DLT definitions from the guidance could have prematurely stopped the early-phase studies of the now approved CAR Ts. In 2023, while designing a first-in-human, phase 1 study of a logic-gated cell therapy, an expert panel of academic cell therapists collaborated with industry partners at A2 Biotherapeutics to assess the practical implications of the FDA guidance. This led the panel to draft the revised recommendations contained herein, which integrate the permissibility of reversible events during dose-escalation for trial sponsors, investigators, health authorities, and other parties who may be involved in future CAR T therapy trials. These expert recommendations balance the safety of patients in early-phase trials with the potential long-term therapeutic opportunities for patients with terminal malignancies.

01 Sep 2025·Transplantation and Cellular Therapy

Improving Patient Access through Value-Based CAR T Delivery: Examples Using a Micro-costing Tool

Review

Author: Shafey, Mona ; Lilley, Helen ; Doble, Brett ; Dickinson, Olivia

The true costs of chimeric antigen receptor T-cell (CAR T) delivery (i.e., all costs except acquisition costs) remain uncertain, with little guidance available to guide accurate estimation. Providers therefore may face challenges in estimating the costs of establishing or expanding CAR T services, particularly if they have limited business expertise or CAR T experience. This risks over- or under-estimation of CAR T delivery costs, with potential for inadequate provider reimbursement, resource challenges, and restricted patient access. Accurate estimation of CAR T delivery costs is an essential component of ensuring value-based healthcare that achieves the best possible patient outcomes, while also ensuring that providers are adequately compensated for service delivery. The purpose of this paper is to demonstrate how value-based CAR T service delivery can be facilitated using an Excel-based micro-costing framework ("tool") to derive accurate and transparent cost estimates that consider the full patient pathway from initial assessment through to 100 days post CAR T infusion. Micro-costing can be used to support robust CAR T business case development and ensure all individual components of the treatment pathway have been accounted for. The tool's flexibility allows providers to model different future scenarios (e.g., changes in the case mix) and test the impact of resource changes (e.g., adjusting staff experience levels) to make informed resourcing decisions. This facilitates identification of opportunities for efficiencies, resource reallocation, and service improvements, and supports providers in delivering CAR T therapy to as many eligible patients as possible. A clear and detailed understanding of CAR T delivery costs can also support validation of reimbursement levels, such as CAR T tariffs, mitigating the risk of provider underpayment for services. The publicly available micro-costing tool is the first to support costing across the full CAR T treatment pathway from initial patient assessment to long-term follow-up. It has the potential to transform provider approaches to CAR T program development, reducing reliance on assumptive costs and uncertainty, and instead offering an evidence-driven approach. Overall, the tool supports value-based and sustainable CAR T therapy delivery, with the aim of ensuring adequate reimbursement for providers while facilitating patient access to this potentially life-saving therapy.

01 Mar 2025·Journal of Managed Care & Specialty Pharmacy

Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.

Article

Author: Chan, Philip K ; Mohammadi, Iman ; Teigland, Christie ; Kilgore, Karl M ; Wade, Sally W

BACKGROUND:

Standard of care (SOC) for relapsed/refractory mantle cell lymphoma (R/R MCL) has included chemoimmunotherapy and targeted therapies (eg, Bruton tyrosine kinase inhibitors [BTKis]). The approval of novel chimeric antigen receptor T-cell (CAR T) therapy in 2020 expanded therapeutic options.

OBJECTIVE:

To compare real-world patient characteristics, treatment patterns, health care resource utilization (HRU), and costs in traditional Medicare and commercially insured patients with R/R MCL treated with CAR T vs non-CAR T SOC (non-CAR T).

METHODS:

Adult patients with R/R MCL who had received 2 or more lines of therapy (LOTs) and continuously enrolled in their health plan between July 1, 2016, and December 31, 2021 (Medicare), or June 30, 2023 (commercial), were stratified into non-CAR T and CAR T cohorts based on therapy received during the study period after MCL diagnosis. Index date was 2L initiation for the non-CAR T cohort and CAR T infusion date for the CAR T cohort. Outcomes included time to next treatment (TTNT), treatment-free interval, MCL-related HRU (inpatient days, emergency department visits, and outpatient visits), and costs (medical and pharmacy).

RESULTS:

2,835 non-CAR T and 122 CAR T patients were included. Compared with non-CAR T patients, CAR T patients were more often commercially insured (27% vs 17.3%; P < 0.01), younger (median age 69 vs 74; P < 0.0001), and male (75.4% vs 64.4%; P = 0.012). Median follow-up after index was 209.5 (CAR T) and 413 (non-CAR T) days. More than one-third (36.9%) of non-CAR T patients received 3L or higher LOT after index and median TTNT decreased with LOT from 689 days (2L) to 184 days (6L). In contrast, only 15% of CAR T patients required additional LOT, and median TTNT post-CAR T was not reached. Duration of treatment-free interval similarly declined with LOT for non-CAR T patients, and the CAR T interval was significantly longer than all non-CAR T LOT. Use of targeted therapies in non-CAR T increased sequentially by LOT (2L: 76%; 6L: 93.2%; BTKi 2L: 26.8%; BTKi 6L: 34.1%). Following CAR T, 9% of patients received targeted therapy, predominantly lenalidomide based. All MCL-related HRU and medical and pharmacy costs were lower post-CAR T than post-index non-CAR T.

CONCLUSIONS:

Non-CAR T was associated with a greater use of post-index LOT, which also had shorter TTNT and treatment-free intervals. This suggests frequent and earlier progression as patients cycle through non-CAR T therapies. Standardized costs were higher in post-index non-CAR T vs post-CAR T episode periods. This suggests that earlier adoption of CAR T may reduce cycling through increasingly more expensive and less effective non-CAR T LOTs, potentially reducing HRU and financial burdens on patients with R/R MCL and the health system.

News (Medical) associated with GC-012F

19 Mar 2026

·www.fiercepharma.com

UPDATED: AstraZeneca to build cell therapy manufacturing hub, R&D center in Shanghai

Alongside revealing plans for new sites, AstraZeneca announced that it will work with partners to launch a new life sciences collaboration program between Shanghai and the U.K. Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to the modality in Shanghai.The move positions the British drugmaker as the first multinational pharmaceutical company to boast end-to-end cell therapy capabilities in China, spanning early-stage research to large-scale commercial production, AZ said in an announcement (Chinese).These new facilities follow a $15 billion investment pledge in China that AZ outlined at the beginning of the year during CEO Pascal Soriot’s visit to the country alongside U.K. Prime Minister Keir Starmer. At that time, AZ highlighted enhancements of its cell therapy and radioconjugate capabilities, new manufacturing facilities and an expanded R&D footprint among its goals. The investment pledge runs through 2030.The new production hub, to be located in the Lin-gang Special Area of the Shanghai Free Trade Zone, will supply autologous CAR-T therapies to China and other Asian markets. These include AZD0120, the BCMA and CD19 dual-targeting CAR-T that AZ obtained as part of its $1 billion acquisition of Gracell Biotechnologies. Complementing the manufacturing facility, a new R&D center in the Zhangjiang High-Tech Park will focus on early research, development of viral vector and plasmid constructs, analytical testing, clinical batch production and registration support.“As one of China’s leading biopharmaceutical hubs, Shanghai has established a robust pathway from foundational research and R&D translation to advanced manufacturing, fostering a vibrant innovation ecosystem,” AZ’s executive vice president of international, Iskra Reic, said in a March 19 release.AZ is doubling down on CAR-T in China after the country recently included several CAR-T products in its first government-led formulary that recommends certain high-cost innovative drugs for commercial insurance. While not part of the state-funded national insurance scheme, the new reimbursement list is expected to facilitate broader commercial coverage of costly but high-clinical-value treatments such as CAR-Ts. Separately on Thursday, AZ said it will build another factory in the Chinese city of Guangzhou for radioconjugates. The site is expected to produce a radiopharmaceutical based on actinium-225 for the treatment of prostate cancer, according to the company.In 2024, AZ bought Fusion Pharmaceuticals along with its PSMA-directed radioconjugate using an actinium-225 payload. The drug is expected to report phase 2 data in previously treated metastatic castration-resistant prostate cancer this year.Together with the Shanghai cell therapy site, the Guangzhou facility will further enhance AZ’s local production capabilities in novel therapeutics, serving as a key pillar as the company expands and diversifies its global supply chain network, AZ said in a release (Chinese).Alongside the revelation of the new sites, AZ announced it will work with partners to launch a new life sciences collaboration program between Shanghai and the U.K. This initiative will “drive joint research, commercialization and business development, ensuring that innovations originating from both the U.K. and Shanghai benefit patients worldwide,” Reic added.As part of the project, AZ has signed a multiparty memorandum of understanding with the Shanghai municipal government’s Science and Technology Commission, the University of Glasgow, King’s College London and HSBC.The latest developments mark a continuation of AZ’s deep involvement in China. With nearly $6.7 billion in local revenue in 2025, AZ is the largest foreign pharma in China, where the company already operates two global R&D centers—in Beijing and Shanghai—as well as four manufacturing bases. “I’m absolutely convinced we need to be in China to collaborate with, partner with Chinese companies, but also to compete and learn,” Soriot said on AZ’s fourth-quarter earnings call last month. “[We need to] learn to compete with them and how they compete, not only commercially, but mostly from an R&D perspective, because the world has changed, and they are increasingly becoming a fundamental part of innovation in our industry. And some of them, at some point, will become global companies.”AZ has frequently bought into innovation developed in China. Its Gracell deal, unveiled in 2023, was the first full acquisition of a Chinese biotech by a multinational pharma. In another CAR-T move, AZ recently penned a potential $630 million deal to obtain AbelZeta Pharma’s 50% share of the China rights to an autologous GPC3-targeting CAR-T therapy. Through a 2023 pact, AZ already owns ex-China rights and the other 50% of the China rights. More broadly, AZ in December fronted $100 million and promised up to $1.91 billion in milestones to acquire ex-China rights to Jacobio Pharma’s pan-KRAS inhibitor. The British pharma then made headlines again in January by signing a massive obesity-focused deal with China’s CSPC Pharmaceuticals that could potentially worth $18.5 billion.Editor's Note: The story was updated at 8 a.m. ET, March 20, to include information about a separate Guangzhou facility.

Cell TherapyAcquisitionImmunotherapy

19 Mar 2026

·endpoints.news

AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plans

AstraZeneca has added more details on how it will use its $15 billion budget to expand in China — and the UK pharma is betting on cell therapy. AstraZeneca said Thursday it will be building a cell therapy research center and a separate factory in Shanghai, where it is headquartered in China. The research center will be home to early-stage research, including viral vector and plasmid development, and manufacturing for clinical-stage assets. The hub, to be named the AstraZeneca Gracell Cell Therapy Innovation Center, reflects the pharma’s purchase of the cell therapy biotech Gracell Biotechnologies announced in 2023. Also on Thursday, AstraZeneca said it signed a memorandum of understanding designed to support clinical research and startup companies in China. The MOU will bring talent from the University of Glasgow and King’s College London, together with AstraZeneca, the Shanghai Science and Technology Commission and HSBC. AstraZeneca’s push for a deeper UK-China partnership comes at a time when the UK is struggling to hold down R&D investments from large drugmakers, including AstraZeneca , Merck and Eli Lilly . On the other hand, China has become a bright spot for early-stage work that’s attracting partnership deals. Meanwhile, AstraZeneca’s standalone cell therapy factory will also make clinical-stage assets. In a Thursday release, it spotlighted that the factory will make its BCMA/CD19 dual-target CAR-T cell therapy called AZD0120. The asset, which was developed using Gracell’s CAR-T tech, is in a Phase 2 study for multiple myeloma and other Phase 1 trials. The manufacturing site is also envisioned to make commercial batches of CAR-T therapies for China and other Asian markets. AstraZeneca currently doesn’t have any CAR-Ts approved in China. In January, it acquired the China rights to market AbelZeta’s Phase 1/2 solid tumor CAR-T asset called C-CAR031. AstraZeneca announced its $15 billion expansion in China in January to expand its manufacturing and R&D operations there. That tally includes a $2.5 billion vaccine plant in Beijing. The UK pharma’s expansion appears to complement its US plans, with the drugmaker having pledged $50 billion there in mid-2025. Several months later, it said it will also list shares directly on the New York Stock Exchange. China makes up 11% of AstraZeneca’s 2025 revenue. It already has manufacturing sites in Wuxi, Taizhou, Qingdao and Beijing, with R&D centers in Beijing and Shanghai. Other drugmakers have also made recent moves to expand in China, but not to the same extent as AstraZeneca. This month, Eli Lilly committed $3 billion to the country over the next 10 years. Pfizer has allocated $1 billion through 2030. As for specific builds, Roche said last year it earmarked 2.04 billion Chinese yuan ($282 million) for a manufacturing plant in Shanghai. In 2024, Sanofi said it would spend €1 billion for a new insulin factory in Beijing, while Daiichi Sankyo said it would invest 1.1 billion Chinese yuan ($152 million) for a new ADC facility.

Phase 2AcquisitionImmunotherapyVaccineCell Therapy

19 Mar 2026

·www.biospace.com

AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy

iStock, ValleraTo The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China. AstraZeneca has committed to building a manufacturing base in Shanghai as part of its push to become the first global drugmaker with end-to-end cell therapy capabilities in China. The Anglo-Swedish drugmaker recently pledged to invest more than $15 billion in China by 2030. At the time, AstraZeneca said the investment would expand its capabilities for making treatments including cell therapies. The company committed to becoming the first global company with end-to-end cell therapy capabilities in China, without sharing details of the infrastructure it will build to achieve that goal. AstraZeneca provided more information in a statement on its Chinese website Thursday. The company is building a commercial cell therapy manufacturing base in a free trade zone in Shanghai to supply CAR-T cell therapies to China and other Asian markets. Establishing the capabilities will equip AstraZeneca to support the planned launches of autologous cell therapies, including its BCMA/CD19 dual-target candidate AZD0120. AstraZeneca acquired the therapy as part of its takeover of China’s Gracell Biotechnologies for around $1 billion upfront. Manufacturing Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032 Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production. March 10, 2026 · 3 min read · Nick Paul Taylor Read more AstraZeneca started a global Phase 3 trial of AZD0120 in multiple myeloma last month. The company is running early-phase studies in lupus, multiple sclerosis and rheumatoid arthritis, establishing itself among the wave of drugmakers exploring cell therapies in autoimmune diseases. The ability of AZD0120 to destroy B cells points to the potential to treat autoimmune diseases that are resistant to existing drugs. AZD0120 is produced from a patient’s own T cells, making manufacturing and logistics key to its commercial prospects. AstraZeneca will need to get T cells to its manufacturing facility, process them and ship the resulting therapy to the patient. Other companies have struggled with CAR-T production, with supply constraining launches and manufacturing failures affecting 18% of patients in one trial. AstraZeneca is investing across the cell therapy supply chain to avoid the setbacks suffered by its peers. As well as setting up a commercial facility in Shanghai, the company will establish an innovation center at a science park in the city. The cell therapy center will support early-stage research, viral vector and plasmid development, analytical testing and clinical manufacturing. Building the facilities will tighten AstraZeneca’s ties to Shanghai, where one of its global R&D centers is based. AstraZeneca has continued to invest in China while contending with challenges, including the detention of its former leader in the country and an investigation into allegations of illegal import. The company shared details of the new Shanghai facilities alongside news that it is working with groups in China and the U.K. to set up a collaboration program. Through the program, AstraZeneca plans to pair Chinese innovation with global scientific and financial resources.

Cell TherapyAcquisitionImmunotherapyPhase 3

100 Deals associated with GC-012F

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	Phase 3	United States	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Japan	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Australia	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Brazil	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Canada	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	France	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Germany	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Italy	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Norway	AstraZeneca PLC	23 Feb 2026
Refractory Multiple Myeloma	Phase 3	Poland	AstraZeneca PLC	23 Feb 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05850234 (DURGA-1, ASH2025) Manual	Phase 1/2	Relapse multiple myeloma \| Refractory Multiple Myeloma	25	AZD0120 (DL1, 1x10^5 cells/kg)	rmhmdiqttg(icxvclpvie) = tcymawliig ityguuwtxv (cmecbqwqun ) View more	Positive	06 Dec 2025
NCT05850234 (DURGA-1, ASH2025) Manual	Phase 1/2	Relapse multiple myeloma \| Refractory Multiple Myeloma	25	AZD0120 (DL2, 3x10^5 cells/kg)	rmhmdiqttg(icxvclpvie) = dsmrnvypjf ityguuwtxv (cmecbqwqun ) View more	Positive	06 Dec 2025
NCT05846347 (ASH2025)	Phase 1/2	Systemic Lupus Erythematosus	15	GC012F	fdyfxwnymi(oewqrvfkkz) = occurred in 14 (mainly Grade 1); two Grade 3 events at the highest dose resolved after steroids ggjdjnwejz (jguephhrnt ) View more	Positive	06 Dec 2025
NCT05858684 (ACR2025)	Phase 1	Systemic Lupus Erythematosus	10	GC012F (AZD0120)	panguezoxh(oldygdpjwc) = Six patients experienced grade 1 CRS, and one patient experienced grade 2 CRS. No cases of immune effector cell-associated neurotoxicity syndrome (ICANS) or grade ≥3 CRS were reported. Other common AEs included hematologic abnormalities, hypogammaglobulinemia, and infections. No fatal adverse events occurred. lazgowhrzg (tkoqweflnc ) View more	Positive	24 Oct 2025
NCT05846347 (PS2146, EHA2025)	Phase 1	Systemic Lupus Erythematosus CD19 \| BCMA	15	GC012F	kzodcnnkfm(ewqmsphraw) = cxhvkugtfq ljobzicyjh (unzbhytvly ) View more	Positive	14 May 2025
NCT04935580 (PS1711, EHA2025)	Phase 1	Multiple Myeloma First line R-ISS stage II or III \| del (17p) \| t (4;14) ... View more	22	GC012F/AZD0120 1x10^5/kg	xnqfutmbtd(anyutushzn) = akixyfkooh vzlhuwohem (upktixnskg ) View more	Positive	14 May 2025
NCT04935580 (PS1711, EHA2025)	Phase 1		22	GC012F/AZD0120 2x10^5/kg	xnqfutmbtd(anyutushzn) = heaalmtdxg vzlhuwohem (upktixnskg ) View more	Positive	14 May 2025
NCT05840107 (PS1731, EHA2025)	Phase 1	Multiple Myeloma First line	9	GC012F/AZD0120 1.5x10^5/kg	ctickhqerj(xxebtaxhmi) = blfnnftczs wroosvadqv (yzfscqvdcs ) View more	Positive	14 May 2025
NCT05840107 (PS1731, EHA2025)	Phase 1	Multiple Myeloma First line	9	GC012F/AZD0120 3x10^5/kg	ctickhqerj(xxebtaxhmi) = bpqrxgmfwt wroosvadqv (yzfscqvdcs ) View more	Positive	14 May 2025
NCT05840107 (ASH2024)	Phase 1	Multiple Myeloma First line	9	AZD0120+地塞米松+硼替佐米+来那度胺	wrbatvibgf(atuckbgxzg) = qfjusakcpg pzdsgqesis (ghoupycgox ) View more	Positive	07 Dec 2024
ChiCTR2100047061 (EHA2024) Manual	Early Phase 1	Diffuse Large B-Cell Lymphoma	12	GC012F	dvckuhdvde(yhxlcfzmgu) = included lymphocytopenia(11/12), neutropenia (11/12), leukopenia (10/12), and thrombocytopenia (3/12) ryfjdjhqjv (vxupidugkj )	Positive	14 May 2024
NCT04935580 (EHA2024) Manual	Phase 1	Multiple Myeloma First line CD19 ... View more	22	GC012F CAR-T therapyGC012F10^5/kg	csqucysbah(kraffskhth) = lkwhquyqvs vgrfcumxzi (ddskewxlyb ) View more	Positive	14 May 2024
NCT04935580 (ASH2023) Manual	Phase 1/2	Multiple Myeloma First line	22	GC012F	gzjuedfmls(ecmtggohli) = eozefswiyf foxurvsbcy (vdomirjxpb ) View more	Positive	11 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

GC-012F

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation